NIHR Maudsley BRC Blog

Our latest news & events

Professor Peter Goadsby elected to the Fellowship of the Royal Society

Professor Peter Goadsby, Theme lead for Pain at the National Institute for Health and Care Research (NIHR) Maudsley Biomedical Research Centre, has been elected to the Fellowship of the Royal Society, a Fellowship of many of the world’s most eminent scientists and the oldest academy in continuous existence.

By NIHR Maudsley BRC at 10 May 2022

The silent and widely impacting cost of Vulvodynia: lessons learned and future recommendations

Multiple studies show that Vulvodynia is a widespread condition that involves persistent pain in the vulva, which refers to external female genitalia. However, Vulvodynia remains largely underdiagnosed and under-researched and has poor treatment options. In this blog, Claudia Chisari, a final year NIHR Maudsley BRC PhD Candidate, discusses Vulvodynia, the lessons learnt from her research, and recommendations to improve support for people living with it.

By NIHR Maudsley BRC at 23 Nov 2021

Professor Peter Goadsby awarded world’s top Brain Prize 2021

Peter Goadsby, Professor of Neurology at King's College London’s Institute of Psychiatry, Psychology & Neuroscience (IoPPN), and Director at the National Institute for Health Research-Wellcome Trust Clinical Research Facility (NIHR CRF), King's College Hospital has been awarded the world’s top Brain Prize from the Lundbeck Foundation for his pioneering migraine research.

By NIHR Maudsley BRC at 4 Mar 2021

10,000 people could benefit from new migraine drug

Fremanezumab, a new drug preventing chronic migraine, has been recommended in final draft guidance from National Institute for health and Care Excellence (NICE) today (12 March 2020) following clinical trials based on research led by King’s College London.

By NIHR Maudsley BRC at 12 Mar 2020

Treatment cuts migraine days by half

A new King’s College London study, published in the New England Journal of Medicine (NEJM), shows treatment with a drug called erenumab cut the number of days with migraine symptoms for 50 per cent of patients.   

By NIHR Maudsley BRC at 30 Nov 2017